CoreCap Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

CoreCap Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$235	Hold	25	–	–	﹤0.01%	2988
2026 Q1	$235	Hold	25	–	–	﹤0.01%	2745
2025 Q4	$204	Buy	+25	New	+$309	﹤0.01%	2813
2024 Q3	–	Sell	-25	Closed	-$1.13K	–	2661
2024 Q2	$1.13K	Hold	25	–	–	﹤0.01%	1382
2024 Q1	$981	Buy	+25	New	+$616	﹤0.01%	2227
2022 Q4	$83	Buy	+25	New	+$96	﹤0.01%	2319
2022 Q3	–	Sell	-25	Closed	–	–	839
2022 Q2	$0	Buy	+25	New	+$242	﹤0.01%	2155
2022 Q1	–	Sell	-25	Closed	-$1K	–	853
2021 Q4	$1K	Buy	+25	New	+$677	﹤0.01%	2085

Other funds holding CRBP

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

SWM

Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return

CoreCap Advisors's CRBP Position: Q2 2026 in Review

CoreCap Advisors held its Corbus Pharmaceuticals (CRBP) position steady in Q2 2026 at 25 shares worth $235. The position accounts for ﹤0.01% of the portfolio, ranked #2988.

CoreCap Advisors first reported a position in CRBP in Q4 2021 and has held it in 8 quarters since. The position peaked at $1.13K in Q2 2024. 6 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

CoreCap Advisors held 25 shares of Corbus Pharmaceuticals worth $235 as of Q2 2026.
CoreCap Advisors left its Corbus Pharmaceuticals share count unchanged in Q2 2026.
Corbus Pharmaceuticals made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2988 holding.
CoreCap Advisors first reported a position in Corbus Pharmaceuticals in Q4 2021 and has held it in 8 quarters since.
CoreCap Advisors's Corbus Pharmaceuticals position peaked at $1.13K in Q2 2024.
6 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.